RXR: from Partnership to Leadership in Metabolic Regulations
Overview
Nutritional Sciences
Authors
Affiliations
Vitamin A signaling occurs through nuclear receptors recognizing diverse forms of retinoic acid (RA). The retinoic acid receptors (RARs) bind all-trans RA and its 9-cis isomer (9-cis RA). They convey most of the activity of RA, particularly during embryogenesis. The second subset of receptors, the rexinoid receptors (RXRs), binds 9-cis RA only. However, RXRs are obligatory DNA-binding partners for a number of nuclear receptors, broadening the spectrum of their biological activity to the corresponding nuclear receptor-signaling pathways. The present chapter more particularly focuses on RXR-containing transcriptional complexes for which RXR is not only a structural component necessary for DNA binding but also acts as a ligand-activated partner. After positioning RXR among the nuclear receptor superfamily in the first part, we will give an overview of three major signaling pathways involved in metabolism, which are sensitive to RXR activation: LXR:RXR, FXR:RXR, and PPAR:RXR. The third and last part is focused on RXR signaling and its potential role in metabolic regulation. Indeed, while the nature of the endogenous ligand for RXR is still in question, as we will discuss herein, a better understanding of RXR activities is necessary to envisage the potential therapeutic applications of synthetic RXR ligands.
The pathogenic role of retinoid nuclear receptor signaling in cancer and metabolic syndromes.
Esposito M, Amory J, Kang Y J Exp Med. 2024; 221(9).
PMID: 39133222 PMC: 11318670. DOI: 10.1084/jem.20240519.
Growth arrest specific protein 6 alleviated white matter injury after experimental ischemic stroke.
Jia J, Xu S, Hu J, Gan Y, Sun M, Xia S J Cereb Blood Flow Metab. 2023; 44(1):77-93.
PMID: 37794790 PMC: 10905636. DOI: 10.1177/0271678X231205078.
Population serum proteomics uncovers a prognostic protein classifier for metabolic syndrome.
Cai X, Xue Z, Zeng F, Tang J, Yue L, Wang B Cell Rep Med. 2023; 4(9):101172.
PMID: 37652016 PMC: 10518601. DOI: 10.1016/j.xcrm.2023.101172.
Bohn T, Hellman-Regen J, de Lera A, Bohm V, Ruhl R Nutr Metab (Lond). 2023; 20(1):34.
PMID: 37582723 PMC: 10426203. DOI: 10.1186/s12986-023-00750-3.
Heterogeneity of the cancer cell line metabolic landscape.
Shorthouse D, Bradley J, Critchlow S, Bendtsen C, Hall B Mol Syst Biol. 2022; 18(11):e11006.
PMID: 36321551 PMC: 9627668. DOI: 10.15252/msb.202211006.